---
title: "FDA approves Enhertu for two HER2-positive early breast cancer indications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286740066.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-05-18T07:49:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286740066.md)
  - [en](https://longbridge.com/en/news/286740066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286740066.md)
---

# FDA approves Enhertu for two HER2-positive early breast cancer indications

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)
- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md)
- [Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | AZN Stock News](https://longbridge.com/en/news/286621973.md)
- [<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>](https://longbridge.com/en/news/286780814.md)
- [AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings](https://longbridge.com/en/news/286677080.md)
- [Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates](https://longbridge.com/en/news/286890035.md)